Related Experiment Video
Updated: Aug 10, 2026

Neuronavigation and Laparoscopy Guided Ventriculoperitoneal Shunt Insertion for the Treatment of Hydrocephalus
Published on: October 14, 2022
Interval debulking with HIPEC in patient with VP shunt
R Shanoada1, J Stephens2, Z R Al-Wahab2
1Obstetrics and Gynecology, Corewell Health Dearborn, Dearborn, MI, USA.
Hyperthermic intraperitoneal chemotherapy (HIPEC) is safe for ovarian cancer patients with ventriculoperitoneal (VP) shunts when managed by a multidisciplinary team. This approach involves intraoperative shunt management and antimicrobial prophylaxis, expanding treatment options.
Area of Science:
- Gynecologic Oncology
- Neurosurgery
- Surgical Oncology
Background:
- Hyperthermic intraperitoneal chemotherapy (HIPEC) offers survival benefits for advanced ovarian cancer.
- Safety of HIPEC in patients with ventriculoperitoneal (VP) shunts is not established.
- Potential risks include shunt infection, chemical ventriculitis, and CNS metastasis.
Related Concept Videos
Venous Thrombosis III: Interprofessional Care
Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care
Peptic Ulcer Disease V: Surgical Management and Nursing Care
Surgical Interventions for Peptic Ulcer Disease
